Skip to main content
. Author manuscript; available in PMC: 2013 Oct 9.
Published in final edited form as: Biol Blood Marrow Transplant. 2009 Sep;15(9):1108–1115. doi: 10.1016/j.bbmt.2009.05.015

Figure 2.

Figure 2

(a) Cumulative incidence of treatment-related mortality (TRM), (b) Actuarial relapse free survival (RFS) for all patients, (c) Cumulative incidence of aGVHD grades II-IV of patients with an absolute lymphocyte count on day +30 (LC30) <0.2 × 109 (solid line), 0.2-1.0 × 109 (dotted line) and ≥1.0 × 109 (dashed line). (d) Actuarial RFS for 77 patients who did not develop aGvHD before day 30.